Expanded Access for ACE-011
- Conditions
- Myelodysplastic Syndrome
- Registration Number
- NCT03724227
- Lead Sponsor
- Celgene
- Brief Summary
This is an expanded access program (EAP) for eligible participants designed to provide access to ACE-011.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NO_LONGER_AVAILABLE
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Exclusion Criteria
Study & Design
- Study Type
- EXPANDED_ACCESS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does ACE-011 target in Myelodysplastic Syndrome patients within the NCT03724227 expanded access program?
How does the expanded access program NCT03724227 compare to standard-of-care treatments for Myelodysplastic Syndrome in terms of clinical outcomes and efficacy?
What biomarkers are used for patient selection and predicting treatment response in the ACE-011 expanded access program (NCT03724227) for Myelodysplastic Syndrome?
What are the known or potential adverse events associated with ACE-011 in the NCT03724227 expanded access program for Myelodysplastic Syndrome, and how are they managed?
Are there related compounds or combination therapies being explored alongside ACE-011 for Myelodysplastic Syndrome, and how do they compare to other competitor drugs in development by Celgene or other pharmaceutical companies?
Trial Locations
- Locations (1)
Celgene
🇺🇸Summit, New Jersey, United States
Celgene🇺🇸Summit, New Jersey, United States